AMES, Iowa, May 31, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation today announced that data from its investigational HyperAcute® Prostate cancer immunotherapy and investigational HyperAcute® Melanoma immunotherapy clinical trials will be presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting to be held June 3-7, 2011 in Chicago, Illinois. A summary of the company's poster presentations is below and full abstracts can be accessed on the ASCO website at www.asco.org.
